Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
Botswana
HIV
cervical cancer
chemoradiation
outcomes
palliative
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
revised:
10
02
2024
received:
20
11
2023
accepted:
13
02
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Cervical cancer associated with human papillomavirus has the highest cancer incidence and mortality for women in Botswana because of a high HIV prevalence and limited screening. This study investigates the significance of HIV on the overall survival (OS) of patients with locally advanced cervical cancer by various treatment categories (curative chemoradiation, definitive radiation [RT] alone, or palliative RT alone). This study included patients diagnosed with cervical cancer between 2013 and 2020, prospectively enrolled in the Botswana Prospective Cancer Cohort. OS based on HIV status and completion of planned treatment regimen was estimated by the Kaplan-Meier method. Comparisons of 2-year OS by HIV status was performed by the log-rank test, univariate and multivariable Cox analyses adjusting for cancer stage, RT dose, number of chemotherapy cycles, and baseline hemoglobin levels. Of 1131 patients diagnosed with stage IB-IVB cervical cancer, 69.8% were women living with HIV (n = 789). For patients receiving curative chemoradiation, HIV status was not significantly associated with OS in unadjusted (p = .987) and adjusted (p = .578) analyses. For RT only treatment and definitive (high-dose) RT alone, HIV status was significantly associated with OS in unadjusted analysis (HR = 1.77, p = .002; HR = 1.95, p = .014), but not in adjusted analysis (p = .227, p = .73). For patients receiving palliative (low-dose) RT, HIV status was not associated with OS in unadjusted (p = .835) or adjusted analysis (p = .359). In Botswana, a resource-limited setting, HIV status had no significant effect on 2-year OS in patients with cervical cancer with well-managed HIV receiving chemoradiation, RT alone, or palliative RT. This demonstrates that patients living with HIV receiving antiretroviral treatment can receive clinically appropriate treatment with no evidence that HIV may lead to poorer outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer associated with human papillomavirus has the highest cancer incidence and mortality for women in Botswana because of a high HIV prevalence and limited screening. This study investigates the significance of HIV on the overall survival (OS) of patients with locally advanced cervical cancer by various treatment categories (curative chemoradiation, definitive radiation [RT] alone, or palliative RT alone).
METHODS
METHODS
This study included patients diagnosed with cervical cancer between 2013 and 2020, prospectively enrolled in the Botswana Prospective Cancer Cohort. OS based on HIV status and completion of planned treatment regimen was estimated by the Kaplan-Meier method. Comparisons of 2-year OS by HIV status was performed by the log-rank test, univariate and multivariable Cox analyses adjusting for cancer stage, RT dose, number of chemotherapy cycles, and baseline hemoglobin levels.
RESULTS
RESULTS
Of 1131 patients diagnosed with stage IB-IVB cervical cancer, 69.8% were women living with HIV (n = 789). For patients receiving curative chemoradiation, HIV status was not significantly associated with OS in unadjusted (p = .987) and adjusted (p = .578) analyses. For RT only treatment and definitive (high-dose) RT alone, HIV status was significantly associated with OS in unadjusted analysis (HR = 1.77, p = .002; HR = 1.95, p = .014), but not in adjusted analysis (p = .227, p = .73). For patients receiving palliative (low-dose) RT, HIV status was not associated with OS in unadjusted (p = .835) or adjusted analysis (p = .359).
CONCLUSIONS
CONCLUSIONS
In Botswana, a resource-limited setting, HIV status had no significant effect on 2-year OS in patients with cervical cancer with well-managed HIV receiving chemoradiation, RT alone, or palliative RT. This demonstrates that patients living with HIV receiving antiretroviral treatment can receive clinically appropriate treatment with no evidence that HIV may lead to poorer outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Mentored Patient Oriented Career Research Development Award
ID : 1-K08CA230170-01A1
Organisme : The Sub- Saharan African Collaborative HIV and Cancer Consortia-U54
ID : 1U54 CA190158- 01
Organisme : Department of Radiation Oncology, University of Pennsylvania
Informations de copyright
© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209‐249. doi:10.3322/caac.21660
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12‐19. doi:10.1002/(sici)1096‐9896(199909)189:1<12::aid‐path431>3.0.co;2‐f
Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, Gates EJ. Cervical cancer as an AIDS‐defining illness. Obstet Gynecol. 1997;89(1):76‐80. doi:10.1016/s0029‐7844(96)00378‐x
Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV‐infected women. JAMA. 2000;283(8):1031‐1037. doi:10.1001/jama.283.8.1031
UNAIDS. Fact Sheet ‐ World AIDS Day 2021 [fact sheet]. 2021. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
Gaolathe T, Wirth KE, Holme MP, et al. Botswana's progress toward achieving the 2020 UNAIDS 90‐90‐90 antiretroviral therapy and virological suppression goals: a population‐based survey. Lancet HIV. 2016;3(5):e221‐e230. doi:10.1016/s2352‐3018(16)00037‐0
Lockman S, Holme MP, Makhema J, et al. Implementation of universal HIV testing and treatment to reduce HIV incidence in Botswana: the Ya Tsie Study. Curr HIV AIDS Rep. 2020;17(5):478‐486. doi:10.1007/s11904‐020‐00523‐0
Dryden‐Peterson S, Bvochora‐Nsingo M, Suneja G, et al. HIV infection and survival among women with cervical cancer. J Clin Oncol. 2016;34(31):3749‐3757. doi:10.1200/jco.2016.67.9613
Matlho K, Randell M, Lebelonyane R, Kefas J, Driscoll T, Negin J. HIV prevalence and related behaviours of older people in Botswana—secondary analysis of the Botswana AIDS Impact Survey (BAIS) IV. Afr J AIDS Res. 2019;18(1):18‐26. doi:10.2989/16085906.2018.1552162
Abu‐Rustum NR, Yashar CM, Bean S, et al. Cervical cancer, Version 1.2020 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2020;18(6):660‐666. doi:10.6004/jnccn.2020.0027
Chuang LT, Temin S, Camacho R, et al. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology Resource‐Stratified Clinical Practice Guideline. J Global Oncol. 2016;2(5):311‐340. doi:10.1200/JGO.2016.003954
Grover S, Bvochora‐Nsingo M, Yeager A, et al. Impact of human immunodeficiency virus infection on survival and acute toxicities from chemoradiation therapy for cervical cancer patients in a limited‐resource setting. Int J Radiat Oncol Biol Phys. 2018;101(1):201‐210. doi:10.1016/j.ijrobp.2018.01.067
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22‐36.
MacDuffie E, Bvochora‐Nsingo M, Chiyapo S, et al. Five‐year overall survival following chemoradiation therapy for locally advanced cervical carcinoma in women living with and without HIV infection in Botswana. Infect Agents Cancer. 2021;16(1):1‐5.
Grover S, Ning MS, Bale M, et al. Chemoradiation versus radiation alone in stage IIIB cervical cancer patients with or without human immunodeficiency virus. Int J Gynecol Cancer. 2021;31(9).
Gallagher KE, LaMontagne DS, Watson‐Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32):4761‐4767.
McClung N, Mathoma A, Gargano JW, et al. HPV prevalence among young adult women living with and without HIV in Botswana for future HPV vaccine impact monitoring. BMC Infect Dis. 2022;22(1):1‐10.
Lemp JM, De Neve JW, Bussmann H, et al. Lifetime prevalence of cervical cancer screening in 55 low‐and middle‐income countries. JAMA. 2020;324(15):1532‐1542.
LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery. Gynecologic Oncology Reports. 2017;22:16‐20.
Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 2003;56(3):778‐787.
Lim A, Sia S. Outcomes of chemoradiotherapy in cervical cancer—the Western Australian experience. Int J Radiat Oncol Biol Phys. 2012;82(4):1431‐1438.
Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26(4):303‐311.
Khamis SI, Mrema AS, Katanga J, Lugina EL. Survival in cervical cancer and its predictors at ocean road cancer institute from January to December 2012. JCO Global Oncol. 2021;7:734‐739.
Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncol. 2002;7(6):492‐508.
Barkati M, Fortin I, Mileshkin L, Bernshaw D, Carrier JF, Narayan K. Hemoglobin level in cervical cancer: a surrogate for an infiltrative phenotype. Int J Gynecol Cancer. 2013;23(4).
Sengayi‐Muchengeti M, Joko‐Fru WY, Miranda‐Filho A, et al. Cervical cancer survival in sub‐Saharan Africa by age, stage at diagnosis and Human Development Index: a population‐based registry study. Int J Cancer. 2020;147(11):3037‐3048.
Yalman D, Aras AB, Ozkök S, et al. Prognostic factors in definitive radiotherapy of uterine cervical cancer. Eur J Gynaecol Oncol. 2003;24(3‐4):309‐314.
Grover S, MacDuffie EC, Wang Q, et al. HIV infection is not associated with the initiation of curative treatment in women with cervical cancer in Botswana. Cancer. 2019;125(10):1645‐1653.
Ntekim A, Campbell O, Rothenbacher D. Optimal management of cervical cancer in HIV‐positive patients: a systematic review. Cancer Med. 2015;4(9):1381‐1393.
Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer‐specific mortality among HIV‐infected patients in the United States. J Clin Oncol. 2015;33(21):2376.
Simonds HM, Botha MH, Neugut AI, Van Der Merwe FH, Jacobson JS. Five‐year overall survival following chemoradiation among HIV‐positive and HIV‐negative patients with locally advanced cervical carcinoma in a South African cohort. Gynecol Oncol. 2018;151(2):215‐220.
Ferreira MP, Coghill AE, Chaves CB, et al. Outcomes of cervical cancer among HIV‐infected and uninfected women treated at the Brazilian National Institute of Cancer (2001–2013). AIDS (Lond). 2017;31(4):523.
Einstein MH, Ndlovu N, Lee J, et al. Cisplatin and radiation therapy in HIV‐positive women with locally advanced cervical cancer in sub‐Saharan Africa: a phase II study of the AIDS malignancy consortium. Gynecol Oncol. 2019;153(1):20‐25. doi:10.1016/j.ygyno.2019.01.023
Van Wijk L, Jemu M, Parker M, Jones G. Tumour and treatment factors influencing the outcome of chemo‐radiation in stage IIB cervical cancer: a single institution experience. Southern African Journal of Gynaecological Oncology. 2018;10(1):21‐26. doi:10.1080/20742835.2018.1441694
Shah S, Xu M, Mehta P, Zetola NM, Grover S. Differences in outcomes of chemoradiation in women with invasive cervical cancer by human immunodeficiency virus status: a systematic review. Practical Radiation Oncology. 2021;11(1):53‐65. doi:10.1016/j.prro.2020.04.007
Gizaw M, Addissie A, Getachew S, et al. Cervical cancer patients presentation and survival in the only oncology referral hospital, Ethiopia: a retrospective cohort study. Infect Agents Cancer. 2017;12(1):61. doi:10.1186/s13027‐017‐0171‐4